Polaris Venture Management Co. V, L.L.C. - Q3 2021 holdings

$14.1 Million is the total value of Polaris Venture Management Co. V, L.L.C.'s 6 reported holdings in Q3 2021. The portfolio turnover from Q2 2021 to Q3 2021 was 14.3% .

 Value Shares↓ Weighting
LYRA  Lyra Therapeutics, Inc.$10,044,000
+13.6%
1,100,8520.0%71.28%
+403.3%
XFOR  x4 Pharmaceuticals Inc.$1,648,000
-18.6%
311,4920.0%11.70%
+260.5%
LIFE  Atyr Pharma Inc.$1,186,000
+86.2%
130,5720.0%8.42%
+724.4%
DARE  Dare Bioscience, Inc.$545,000
-11.7%
326,2400.0%3.87%
+291.1%
GNCA  Genocea Biosciences, Inc.$379,000
-18.0%
197,3450.0%2.69%
+263.5%
PULM  Pulmatrix, Inc.$288,000
-23.0%
359,4410.0%2.04%
+241.2%
FATE ExitFate Therapeutics, Inc.$0-569,889
-100.0%
-79.24%
Original filings

The following EDGAR filing(s) were analyzed to create this report:

  • View 13F-HR filed 2021-11-12
Signatures

The EDGAR filing(s) were signed by:

Top long-term holdings
NameQuarters ownedLatest quarter ownedMax weighting
Fate Therapeutics, Inc.30Q2 202179.2%
Atyr Pharma Inc.26Q3 202115.1%
Trevena, Inc.22Q2 201924.9%
Genocea Biosciences, Inc.21Q1 201932.5%
Selecta Biosciences, Inc.20Q1 202139.5%
T2 Biosystems, Inc.20Q2 201936.1%
Dare Bioscience, Inc.17Q3 20213.9%
Pulmatrix, Inc.16Q1 201915.4%
Cerulean Pharma Inc13Q2 201716.2%
Kala Pharmaceuticals, Inc.11Q1 202037.1%

View Polaris Venture Management Co. V, L.L.C.'s complete holdings history.

Latest filings
TypeFiled
32022-03-30
13F-HR2021-11-12
13F-HR2021-08-12
13F-HR2021-05-12
13F-HR2021-02-12
13F-HR2020-11-12
13F-HR2020-08-12
13F-HR2020-05-14
42020-05-06
32020-04-30

View Polaris Venture Management Co. V, L.L.C.'s complete filings history.

Compare quarters

Export Polaris Venture Management Co. V, L.L.C.'s holdings